Loading stock data…
SMMT
$14.29+0.18 (+1.28%)
After Hours$14.29+0.00 (+0.00%)· Last close Jun 9
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Summit Therapeutics Inc. in the Healthcare sector is trading at $14.29 with a market capitalization of $12.9B. Wall Street consensus targets $28.46 (13 analysts), implying a +99.2% move over the next 12 months. The stock is currently near its 52-week low of $13.81, remaining 22.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +99.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.29
Potential Downside
0%
Whystock Fair Value$14.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$28.46+99.2%
Range$7.64 – $44.68
Fundamentals
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.90B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-220.92%
Volume
Today's trading volume
4.76M
Recent News
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho healthcare strategist Jared Holz reframed the sector, arguing that years of underperformance have turned drug stocks from a defensive holding into something more interesting for growth-heavy portfolios. “I think you just have to look ... Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock
Those following along with Summit Therapeutics Inc. ( NASDAQ:SMMT ) will no doubt be intrigued by the recent purchase...
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 best large cap stocks under $30 with highest upside potential. On May 31, Summit Therapeutics Inc. (NASDAQ:SMMT) presented new clinical data from the international Phase II AK112-206 trial during the American Society of Clinical Oncology. Co-sponsored alongside Akeso, this multisite study evaluates the potential first-in-class bispecific […]
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best high short interest stocks with highest upside potential. On May 31, Summit Therapeutics announced positive Phase III overall survival/OS results from the HARMONi-6 trial, which evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in patients with advanced squamous non-small cell lung cancer/NSCLC. The study showed that […]